Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Ist Teil von
Clinical cancer research, 2013-05, Vol.19 (10), p.2607-2612
Ort / Verlag
Philadelphia, PA: American Association for Cancer Research
Erscheinungsjahr
2013
Quelle
MEDLINE
Beschreibungen/Notizen
Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are many factors that can influence the exact moment of when disease progression is recorded. In this overview, we review the circumstances that can devalue the use of PFS as a primary endpoint and attempt to provide a pathway for a future desired state when PFS will become not just a secondary alternative to overall survival but rather an endpoint of choice.